دورية أكاديمية
أعرض في EDS

Predictive Value of Tumor-Infiltrating Lymphocytes and Ki-67 for Pathological Response to Total Neoadjuvant Therapy in Rectal Cancer.

التفاصيل البيبلوغرافية
العنوان: Predictive Value of Tumor-Infiltrating Lymphocytes and Ki-67 for Pathological Response to Total Neoadjuvant Therapy in Rectal Cancer.
المؤلفون: Mohammed A; Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. amrallaabdelmoneem@yahoo.com., Bakry A; Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Gharieb S; Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Hanna A; Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Obaya A; Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Abdelhady W; Surgical Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Metwalli A; Surgical Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
المصدر: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Jun; Vol. 55 (2), pp. 869-876. Date of Electronic Publication: 2024 Feb 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press
مواضيع طبية MeSH: Rectal Neoplasms*/therapy , Rectal Neoplasms*/pathology , Rectal Neoplasms*/metabolism , Lymphocytes, Tumor-Infiltrating*/immunology , Neoadjuvant Therapy*/methods , Ki-67 Antigen*/metabolism , Ki-67 Antigen*/analysis, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Prospective Studies ; Predictive Value of Tests ; Prognosis ; Treatment Outcome ; Aged, 80 and over
مستخلص: Purpose: Patients with locally advanced rectal cancer (LARC) who underwent total neoadjuvant therapy (TNT) showed an increase in the percentage of complete pathological response (pCR). The purpose of this study was to determine the correlation between Ki-67, tumor-infiltrating lymphocytes (TIL), and TNT in LARC patients.
Method: In total, one hundred fifty-nine patients with LARC were included in this prospective study. The international working group was used to categorize the TIL into three groups based on the percentage and density of staining: group 0 (0-10%), group 1 (11-59%), and group 2 (≥ 60%). Ki-67 expression was classified as low (≤ 50%) or high (> 50%).
Result: Most patients had tumor grade III (74.2%) and T2-T3 (78.6%). Lymph node involvement (48.7%) and tumor size ≥ 3 cm were detected in approximately half of the patients. Forty-four percent of patients had a high Ki-67 index; 15.7% of patients belonged to group 1, and 21.4% belonged to group 2. pCR was detected in 18.2% of the patients. TIL and Ki-67 levels were significantly correlated with pCR (p = 0.001 and 0.003 for multivariate analysis and 0.001 and 0.03 for univariate analysis, respectively).
Conclusion: There was a statistically significant correlation between Ki-67, TIL, and pCR following TNT protocol, which may help maximize the therapeutic outcome.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72(1):7–33. (PMID: 10.3322/caac.21708)
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2020;70(3):145–64. (PMID: 10.3322/caac.21601)
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33. (PMID: 10.1200/JCO.2011.40.1836)
Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD, Wong WD. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829–36. (PMID: 10.1097/01.sla.0000161980.46459.96)
Reugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7. (PMID: 10.1016/S1470-2045(14)71199-4)
Mohammed AA, Mostafa Elsayed F, Algazar M, Rashed HE. Predictive and prognostic value of tumor- infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in triple negative breast cancer. Gulf J Oncolog. 2022;1(38):53–60.
Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, et al. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132(3):895–915. (PMID: 10.1007/s10549-011-1837-z)
Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P, Xu X. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC8 stratification. Oncol Rep. 2020;43(4):1187–98.
Omejc M, Potisek M. Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy. Radiol Oncol. 2017;52(1):30–5. (PMID: 10.1515/raon-2017-0059)
García-Aguilar J, de Anda EH, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Diseases of the colon & rectum. 2003 Mar 1;46(3):298-304.
van der Valk MJ, Hilling DE, Bastiaannet E, Kranenbarg EM, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJ, Ahlberg M. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. The Lancet. 2018 Jun 23;391(10139):2537-45.
Sychev S, Ponomarenko A, Chernyshov S, Alekseev M, Mamedli Z, Kuzmichev D, Polynovskiy A, Rybakov E. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol. 2023;39(4):289–300. (PMID: 10.3393/ac.2022.00920.0131)
Bitterman DS, Resende Salgado L, Moore HG, Sanfilippo NJ, Gu P, Hatzaras I, Du KL. Predictors of complete response and disease recurrence following chemoradiation for rectal cancer. Front Oncol. 2015;5:286–9. (PMID: 10.3389/fonc.2015.00286)
Hammarström K, Imam I, Mezheyeuski A, Ekström J, Sjöblom T, Glimelius B. A comprehensive evaluation of associations between routinely collected staging information and the response to (chemo) radiotherapy in rectal cancer. Cancers 2020; 22; 13 (1):16.
Suwanthanma W, Kitudomrat S, Euanorasetr C. Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment. Medicine (Baltimore). 2021; 24; 100(38):e27366.
Shin JK, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, Park YA. Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer. Sci Rep. 2022; 3;12(1):7145.
Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA – A predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013;56(7):859–68. (PMID: 10.1097/DCR.0b013e31828e5a72)
Shao K, Zheng R, Li A, Li X, Xu B. Clinical predictors of pathological good response in locally advanced rectal cancer. Radiat Oncol. 2021;16(1):1–8. (PMID: 10.1186/s13014-020-01741-x)
Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2013;56(6):698–703. (PMID: 10.1097/DCR.0b013e3182837e5b)
Kleiman A, Al-Khamis A, Farsi A, Kezouh A, Vuong T, Gordon PH, Vasilevsky CA, Morin N, Faria J, Ghitulescu G, Boutros M. Normalization of CEA levels post-neoadjuvant therapy is a strong predictor of pathologic complete response in rectal cancer. J Gastrointest Surg. 2015;19(6):1106–12. (PMID: 10.1007/s11605-015-2814-3)
Garland ML, Vather R, Bunkley N, Pearse M, Bissett IP. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer Int J Colorectal Dis 2014; 29 (3): 301–307. 5.
Peng H, Wang C, Xiao W, Lin X, You K, Dong J, Wang Z, Yu X, Zeng Z, Zhou T, Gao Y, Wen B. Analysis of clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer. 2018;9(15):2687–92. (PMID: 10.7150/jca.25493)
Tan Y, Fu D, Li D, Kong X, Jiang K, Chen L, Yuan Y, Ding K. Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: a population-based analysis. Front Oncol. 2019;9:497. (PMID: 10.3389/fonc.2019.00497)
Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2016;23(4):1177–86. (PMID: 10.1245/s10434-015-5017-y)
Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013;119(24):4231–41. (PMID: 10.1002/cncr.28331)
Yildirim E, Bektas S, Pelen Z, Yanik I, Er AM, Cengel F, Gumuskaya PÖ. Histopathological, radiological, and demographic factors predicting the response to neoadjuvant therapy for rectal cancer. J Gastrointest Cancer. 2022;53(1):22–30. (PMID: 10.1007/s12029-021-00697-9)
Malekzadeh Moghani M, Alahyari S, Moradi A, et al. Pathological predictors of response to neoadjuvant treatment in rectal carcinoma. J Gastrointest Cancer. 2021;52(2):690–5. (PMID: 10.1007/s12029-020-00450-8)
Sun X, Kaufman PD. Ki-67: More than a proliferation marker. Chromosoma. 2018;127(2):175–86. (PMID: 10.1007/s00412-018-0659-8)
Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):3360. (PMID: 10.1038/s41598-020-60255-4)
Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, et al. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst. 2016;12;108 (8).
Matsutani S, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Hirakawa K, Ohira M. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 2018;109(4):966–79. (PMID: 10.1111/cas.13542)
Orhan A, Khesrawi F, Tvilling Madsen M, Peuliche Vogelsang R, Dohrn N, Kanstrup Fiehn AM, Gögenur I. Tumor-infiltrating lymphocytes as biomarkers of treatment response and long-term survival in patients with rectal cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;27;14 (3):636.
Kucukgoz,Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, Khatib G, Zeren H, Vardar MA, Altintas A. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet. 2014;289(2):393–398.
Liu Q, Ran D, Wang L, Feng J, Deng W, Mei D, Peng Y, Du C. Association between Ki67 expression and therapeutic outcome in colon cancer. Oncol Lett. 2023;10;25(6):272.
Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 2011;6:49. (PMID: 10.1186/1748-717X-6-49)
Dalle Fratte C, Mezzalira S, Polesel J, De Mattia E, Palumbo A, Buonadonna A, Palazzari E, De Paoli A, Belluco C, Canzonieri V, Toffoli G, Cecchin E. A panel of tumor biomarkers to predict complete pathological response to neoadjuvant treatment in locally advanced rectal cancer. Oncol Res. 2022; 31;28 (9):847–855.
Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci. 2020;111(1):23–35. (PMID: 10.1111/cas.14223)
Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13. (PMID: 10.1016/S2468-1253(17)30074-2)
Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6): e180071. (PMID: 10.1001/jamaoncol.2018.0071)
A. L. Gentile , C. Pinto , C. Ceccarelli , F. Di Fabio , C. Funaioli , C. LongobardiM. L. Tardio , D. Cuicchi , B. Iacopino , A. A. Martoni Impact of biomarker dynamic profile and pathological response induced by neoadjuvant chemoradiotherapy in rectal cancer. JCO 24, no. 18_suppl (June 20, 2006) 3614–3614.
Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res 2019; 25 (18): 5561–5571. 114.
فهرسة مساهمة: Keywords: Ki-67; Local advanced rectal cancer; Pathological response; Total neoadjuvant therapy; Tumor-infiltrating lymphocytes
المشرفين على المادة: 0 (Ki-67 Antigen)
تواريخ الأحداث: Date Created: 20240215 Date Completed: 20240619 Latest Revision: 20240628
رمز التحديث: 20240629
DOI: 10.1007/s12029-024-01026-6
PMID: 38358621
قاعدة البيانات: MEDLINE
الوصف
تدمد:1941-6636
DOI:10.1007/s12029-024-01026-6